Shenfu Injection for Intradialytic Hypotension: A Systematic Review and Meta-AnalysisReport as inadecuate




Shenfu Injection for Intradialytic Hypotension: A Systematic Review and Meta-Analysis - Download this document for free, or read online. Document in PDF available to download.

Evidence-Based Complementary and Alternative Medicine - Volume 2014 2014, Article ID 279853, 11 pages -

Review Article

The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

Nephropathy Department, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Emergency Department, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Received 9 July 2014; Revised 9 September 2014; Accepted 19 September 2014; Published 22 December 2014

Academic Editor: Tzeng-Ji Chen

Copyright © 2014 Yenan Mo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To evaluate the effectiveness and safety of Shenfu injection SFI for intradialytic hypotension IDH. Methods. A systematic review of data sources published as of April 2014 was conducted. These included the Cochrane Central Register of Controlled Trials 2014 issue 4, Pubmed, Embase, CBM, CNKI, VIP, and Wangfang Data. Randomized controlled trials RCTs involving SFI for treatment and prevention of IDH were identified. Two researchers independently selected articles, extracted data, assessed quality, and cross checked the results. Revman 5.2 was used to analyze the results. Results. Eight RCTs were included. The meta-analysis indicated that compared with conventional therapies alone, SFI could elevate systolic blood pressure SBP, increase the clinical effective rate, decrease the incidence of hypotension, increase serum albumin ALB levels, and reduce C-reactive protein CRP levels without serious adverse effects. GRADE Quality of Evidence. the quality of SBP, the effective rate, ALB, and CRP were low, and hypotension incidence and DBP were very low. Conclusions. SFI is more effective than conventional therapies for prevention and treatment of IDH. However, a clinical recommendation is not warranted due to the small number of studies included and low methodology quality. Multi-center and high-quality RCTs with large sample sizes are needed to provide stronger evidence.





Author: Yenan Mo, Xusheng Liu, Xindong Qin, Jing Huang, Zhiren He, Junjie Lin, Qinqing Hu, Youqing Cai, Zhuangzhu Liu, and Lixin

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents